The successive PLI disbursements validate our disciplined execution and sustained commitment to strengthening India’s domestic pharmaceutical manufacturing capabilities
Approval marks Venus Remedies’ first anti-infective marketing authorization in Indonesia and enables the country’s first generic entry for this critical antibiotic combination
India should explore Sustainability-Linked Incentives (SLI) targeting innovations in the 12 principles of green chemistry
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
This development marks a substantial improvement in the company's financial position and reflects strengthened promoter confidence
India has deep strengths in reverse engineering and API development, while Russia has strong capabilities in certain vaccines, biologicals, and niche therapeutic segments. Collaboration can significantly shorten R&D timelines
PLI scheme for Bulk Drugs has a total budgetary outlay of Rs. 6,940 crore
With US$ 30.46 billion in exports and robust manufacturing capabilities, the industry is poised to expand into high-value drugs while strengthening ESG and compliance standards
Building a transparent, data-driven supply chain and self-reliant API ecosystem remains critical to reducing import dependence
The event will be attended by 35,000+ industry professionals
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
